<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084305</url>
  </required_header>
  <id_info>
    <org_study_id>040211</org_study_id>
    <secondary_id>04-HG-0211</secondary_id>
    <nct_id>NCT00084305</nct_id>
  </id_info>
  <brief_title>Analysis of Specimens From Individuals With Pulmonary Fibrosis</brief_title>
  <official_title>Analysis of Specimens From Individuals With Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens&#xD;
      procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated&#xD;
      extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may&#xD;
      contribute to our understanding of the pathogenic mechanisms of pulmonary fibrosis. The&#xD;
      purpose of this protocol is to procure and analyze blood, genomic DNA, and specimens by&#xD;
      bronchoscopy, lung biopsy, lung transplantation, extra-pulmonary biopsies, or post-mortem&#xD;
      examination from subjects with pulmonary fibrosis. In addition, blood, genomic DNA,&#xD;
      clinically-indicated extra-pulmonary biopsies, as well as bronchoscopy and post-mortem&#xD;
      examination specimens may be procured and analyzed from relatives of subjects with hereditary&#xD;
      forms of pulmonary fibrosis; blood, genomic DNA, and bronchoscopy specimens may be procured&#xD;
      from healthy research volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens&#xD;
      procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated&#xD;
      extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may&#xD;
      contribute to our understanding of the pathogenic mechanisms of pulmonary fibrosis. The&#xD;
      purpose of this protocol is to procure and analyze blood, genomic DNA, and specimens by&#xD;
      bronchoscopy, lung biopsy, lung transplantation, extra-pulmonary biopsies, or post-mortem&#xD;
      examination from subjects with pulmonary fibrosis. In addition, blood, genomic DNA,&#xD;
      clinically-indicated extra-pulmonary biopsies, as well as bronchoscopy and post-mortem&#xD;
      examination specimens may be procured and analyzed from relatives of subjects with hereditary&#xD;
      forms of pulmonary fibrosis; blood, genomic DNA, and bronchoscopy specimens may be procured&#xD;
      from healthy research volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2004</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procure and analyze</measure>
    <time_frame>Ongoing</time_frame>
    <description>The objectives and specific aims of this protocol are to procure and analyze blood and cell/tissue specimens from individuals with pulmonary fibrosis, relatives of subjects with familial pulmonary fibrosis, and healthy research volunteers.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Healthy Volunteers</condition>
  <condition>Hermansky-Pudlak Syndrome (HPS)</condition>
  <arm_group>
    <arm_group_label>Family</arm_group_label>
    <description>Family members of patients with pulmonary fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Fibrosis</arm_group_label>
    <description>Patients with pulmonary fibrosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary fibrosis@@@@@@&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Individuals who are 18 years of age or older with any of the following:&#xD;
&#xD;
          1. Idiopathic pulmonary fibrosis [defined by the American Thoracic Society/European&#xD;
             Respiratory Society guidelines],&#xD;
&#xD;
          2. Familial pulmonary fibrosis [defined as idiopathic pulmonary fibrosis in two or more&#xD;
             first-degree relatives],&#xD;
&#xD;
          3. Relatives of patients with hereditary pulmonary fibrosis,&#xD;
&#xD;
          4. Hermansky-Pudlak syndrome (diagnosed by paucity or deficiency of platelet dense bodies&#xD;
             on whole mount electron microscopy or by genetic testing),&#xD;
&#xD;
          5. Pulmonary fibrosis associated with collagen vascular diseases or autoinflammatory&#xD;
             disorders,&#xD;
&#xD;
          6. Pulmonary fibrosis post-COVID-19 [i.e., pulmonary fibrosis in an individual recovering&#xD;
             from SARS-CoV-2 infection], or&#xD;
&#xD;
          7. Healthy research volunteers by history and indicated tests (individuals without&#xD;
             history of chronic pulmonary disorder, collagen vascular disease, or bleeding&#xD;
             disorder).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Individuals with any of the following:&#xD;
&#xD;
          1. Significant inhalational exposure to fibrogenic fibers or dusts or exposure to drugs&#xD;
             associated with pulmonary fibrosis,&#xD;
&#xD;
          2. Uncontrolled ischemic heart disease,&#xD;
&#xD;
          3. Uncorrectable bleeding diathesis,&#xD;
&#xD;
          4. Pregnancy or lactation, or&#xD;
&#xD;
          5. Inability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernadette R Gochuico, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Human Genome Research Institute (NHGRI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernadette R Gochuico, M.D.</last_name>
    <phone>(301) 451-7979</phone>
    <email>gochuicb@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2004-HG-0211.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>February 28, 2021</verification_date>
  <study_first_submitted>June 9, 2004</study_first_submitted>
  <study_first_submitted_qc>June 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2004</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchoscopy</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>Lung Biopsy (Clinically-Indicated)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Hermanski-Pudlak Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

